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Background/Aims: Measures of body composition, including visceral adipose 
tissue (VAT), subcutaneous adipose tissue (SAT), and skeletal muscle area (SMA), 
are considered important prognostic factors in chronic diseases. The association 
of these measures with auto-inflammatory disorders, such as anti-neutrophil cy-
toplasmic antibody-associated vasculitis (AAV), remains unclear. We investigated 
the clinical significance of VAT, SAT, and SMA in patients with AAV.
Methods: Patients with AAV subjected to chest computed tomography (CT), ab-
dominal CT, or positron emission tomography-CT on diagnosis of AAV were 
evaluated. Quantitative assessment of VAT, SAT, and SMA was performed at the 
third lumbar vertebral level and computed by summing the pixel attenuation 
for tissue-specific Hounsfield units in the corresponding region. Associations of 
VAT, SAT, and SMA with clinical and laboratory data and clinical outcome mea-
sures were evaluated.
Results: Of the 117 patients, 61 (52.1%) were classif ied as having microscopic 
polyangiitis, 28 (23.9%) as granulomatosis with polyangiitis, and 28 (23.9%) as eo-
sinophilic granulomatosis with polyangiitis. VAT significantly correlated with 
age, weight, body mass index (BMI), and Birmingham Vasculitis Activity Score, 
whereas SAT correlated with weight, BMI, and creatinine levels. A significant as-
sociation was found between SMA and age, height, weight, BMI, and the Five-Fac-
tor Score. Cox proportional hazards analysis showed that creatinine levels (odds 
ratio [OR], 1.346; 95% confidence interval [CI], 1.034 to 1.753; p = 0.027) and high 
VAT (OR, 7.137; 95% CI, 1.343–37.946; p = 0.021) were independently associated with 
all-cause mortality during follow-up.
Conclusions: Evaluation of VAT using CT is useful for estimating disease activity 
and all-cause mortality in patients with AAV.
Keywords: Body composition; Computed tomography; Prognosis; Anti-neutrophil 
cytoplasmic antibody-associated vasculitis; Visceral adipose tissue
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INTRODUCTION
Anti-neutrophil cytoplasmic antibody (ANCA)-associ-
ated vasculitis (AAV) is an auto-inflammatory disorder 
characterized by the production of pathogenic ANCAs 
and necrotizing inflammation in the vessels [1]. Three 
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different diseases, microscopic polyangiitis (MPA), gran-
ulomatosis with polyangiitis (GPA), and eosinophil-
ic granulomatosis with polyangiitis (EGPA), comprise 
this disease entity, which is differentiated by the dif-
ferent organs affected and the pathologic findings [2]. 
Although improvements in therapeutic approaches in 
recent decades have led to significant favorable clinical 
outcomes, substantially higher mortality has been still 
reported in patients with AAV. In the European Vascu-
litis Society cohort data, the 1- and 5-year survival rates 
for patients with AAV were 88% and 78%, respectively 
[3], and a population based study performed in southern 
Sweden showed that 1-, 5-, and 10-year survival rates for 
patients with AAV were 87%, 70%, and 55%, respectively 
[4]. Moreover, a recent meta-analysis has demonstrated 
that the risk of mortality estimates was over 2.7-fold in 
comparison to the general population [5]. In particular, 
clinical factors such as age, sex, and impaired kidney 
function, and higher disease activity has been suggest-
ed to be associated with mortality, but with discordant 
results [4,6]. In this context, much attention has been 
persistently given to the discovery of predictive factors 
of prognosis in patients with AAV.
Body composition refers to the distribution of fat and 
lean mass within the body, which could be measured 
by various methods including bioelectrical impedance 
analysis (BIA), dual-energy X-ray absorptiometry (DXA), 
computed tomography (CT), and magnetic resonance 
imaging (MRI) [7,8]. While it was previously understood 
that body composition is a merely a measure of physical 
fitness, a growing body of evidence now suggests that 
changes in body composition are associated with alter-
ations of the immune response and are associated with 
health outcomes of patients [9,10]. Among various mea-
sures to assess body composition, visceral adipose tissue 
(VAT), subcutaneous adipose tissue (SAT), and skeletal 
muscle area (SMA) are now considered important prog-
nostic factors in chronic diseases. Typically, VAT was 
reported to be associated with excessive risk of mortal-
ity in patients with cancer, while an inverse correlation 
between SAT and SMA with patient prognosis has also 
been shown [11]. Nevertheless, the clinical significance of 
VAT, SAT, and SMA in patients with auto-inflammatory 
disorders, especially AAV has not been well described. 
Therefore, the aims of the present study were to (1) eval-
uate the association of VAT, SAT, and SMA with clinical 
and laboratory data and (2) elucidate the prognostic sig-
nificance of VAT, SAT, and SMA in patients with AAV.
METHODS
Patient selection
The medical records of patients who were diagnosed as 
AAV between October 2000 and December 2018 were 
retrospectively reviewed. The inclusion criteria were 
as follows: (1) patients who were diagnosed with AAV 
at Severance Hospital in Seoul, Korea; (2) patients with 
had no serious comorbidities that could mimic AAV at 
diagnosis as identified in the 10th revised Internation-
al Classification of Diseases; (3) patients who had un-
dergone either chest CT, abdominal CT, and positron 
emission tomography (PET)-CT to determine the site of 
inflammation when the diagnosis of AAV was made. All 
patients were reclassified into AAV subtypes as per the 
2007 European Medicines Agency algorithm for AAV 
and the descriptions provided by the 2012 Chapel Hill 
Consensus Conference definitions [2,12]. Ultimately, 117 
patients with AAV were included in the study. Age-, sex-, 
and body mass index (BMI)-matched healthy controls (n 
= 50) included for comparison were recruited from those 
who had undergone abdominal CT for a regular health 
check up at the Hospital’s health examination center. 
This study was approved by the Institutional Review 
Board of Severance Hospital (IRB No. 4-2017-0673) and 
performed in accordance with the principles set by the 
Declaration of Helsinki, and the requirement for writ-
ten informed consent was waived because of the retro-
spective nature of the study.
Collection of clinical information 
The clinical information collected included AAV vari-
ants, ANCA types, demographic data, clinical manifes-
tations, comorbidities, and laboratory data, which were 
assessed at the date when the diagnosis of AAV was 
made. Demographic data consisted of age, sex, height, 
weight, BMI, and the Birmingham Vasculitis Activity 
Score (BVAS), and Five-Factor Score (FFS) (2009), which 
were calculated from the medical records of patients 
[13,14]. The clinical manifestations were collected as per 
the items in the BVAS and FFS (2009). Owing to the 
difference in weights between the revised BVAS/GPA 
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and BVAS 3.0, the BVAS for patients with GPA was also 
calculated using BVAS 3.0 [15]. Comorbidities included 
the presence of hypertension, diabetes mellitus, and 
dyslipidemia prior to the diagnosis of AAV. Patients 
were defined as having the following medical condition 
previously when they were currently on medications or 
clearly stated that they were diagnosed for the corre-
sponding comorbidities. As for laboratory data, the re-
sults of white blood cell, neutrophil, and platelet counts; 
erythrocyte sedimentation rate (ESR); C-reactive protein 
(CRP); serum albumin, total cholesterol, fasting blood 
glucose, and creatinine levels were obtained.
Estimation of VAT, SAT, SMA, and sarcopenia
Acquired chest CT, abdominal CT, and PET-CT images 
were used for the quantitative assessment of the VAT, 
SAT, and SMA. All analyses were performed at the third 
lumbar vertebral (L3) level using the Aquarius iNtuition 
Viewer version 4.4.12 (TeraRecon Inc., Fremont, CA, 
USA). The L3 level was defined as the slice including the 
middle of the third lumbar vertebrae. VAT, SAT, and 
SMA were computed identically by summing the pixel 
attenuation for tissue-specific Hounsfield unit: (1) adi-
pose tissue, –190 to –30 and (2) skeletal muscle, –29 to 
+150 [16]. VAT was manually separated from SAT at the 
identical slice using the boundary inner to the abdom-
inal muscle wall. Representative images were used to 
estimate VAT, SAT, and SMA are shown in Fig. 1. Sarco-
penia was defined as a L3 skeletal muscle index of ≤ 49 
cm2/m2 for men and ≤ 31 cm2/m2 for women based on a 
previous study [17]. All measurements were performed 
by an experienced radiology technician who was blinded 
to the clinical information. 
Definition of obesity, clinical outcome measures, 
and immunosuppressive medications 
Patients with and without obesity were divided in ac-
cordance with the Asian-Pacific cut-off values of BMI 
≥ 25 kg/m2 [18]. For the clinical outcome measures, all-
cause mortality, end-stage renal disease (ESRD), disease 
relapse, acute coronary syndrome (ACS), and stroke were 
investigated during follow-up. We defined all-cause 
mortality as death attributable to any reason during 
follow-up, and ESRD as an impairment of renal func-
tion requiring dialysis. Disease relapse was defined as 
recurrence or new onset of disease with active vasculitis, 
as described previously [19]. The definition of ACS was 
set as either myocardial infarction or unstable angina 
and stroke as either hemorrhagic or ischemic [20,21]. 
Immunosuppressive medications that were used to the 
patients after diagnosis was counted by using the Hos-
pital’s electronic medical record system.
Statistical analysis
All statistical analyses were conducted using MedCalc 
software version 19 (MedCalc Software, Ostend, Bel-
gium). Continuous variables are expressed as medians 
(interquartile ranges) and categorical variables as num-
bers (percentages). Significant differences between the 
two groups were analyzed using the Mann-Whitney U 
test for continuous variables and chi-square or Fisher’s 
exact tests for categorical variables. High VAT, SAT, 
SMA, and VAT-to-SAT ratio was defined as the respec-
tive values over the median values, and the correlation 
between continuous variables was estimated by Pear-
son’s correlation analysis. Comparison of the cumula-
tive survival rate between groups was analyzed using the 
Kaplan-Meier survival analysis and the log-rank test. 
Multivariable Cox proportional hazards analysis using 
variables with significance in univariable analysis was 
used to identify predictive factors associated with all-
cause mortality and ESRD. The p values < 0.05 were con-
sidered statistically significant in all analyses.
RESULTS 
Baseline characteristics of patients
Baseline characteristics of the patients that were includ-
ed in the study are described in Table 1. Sixty-one (52.1%) 
patients were classified as MPA, 28 (23.9%) as GPA, and 
28 (23.9%) as EGPA. Seventy-nine (67.5%), 18 (15.4%), 
and 25 (21.4%) patients had myeloperoxidase-ANCA (or 
perinuclear ANCA), proteinase 3-ANCA (or cytoplasmic 
ANCA), and negative ANCAs, respectively. The median 
age of the patients was 61 years and 74 (63.2%) patients 
were female. The median height, weight, and BMI of the 
patients were 1.6 m, 56.0 kg, and 22.0 kg/m2, respective-
ly. Based on the cut-off BMI of ≥ 25 kg/m2, a total of 20 
(17.1%) and 97 (82.9%) patients were assigned to the obese 
group and non-obese groups, respectively. Patients were 
followed up for a median duration of 27.3 months after 
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the diagnosis of AAV. Among clinical manifestations, 
pulmonary events (65.8%) were the most common, fol-
lowed by renal and general manifestations (60.7% and 
49.6%). The comorbidities of hypertension, diabetes 
mellitus, and dyslipidemia were found in 39.3%, 19.7%, 
and 6.8% of patients, respectively. Concerning labora-
tory data, the median white blood cell, neutrophil, and 
platelet counts, ESR, and CRP levels were 9,800/mm3, 
7,160/mm3, 331 × 103/mm3, 68.0 mm/hr, and 24.0 mg/L, 
respectively. The median total cholesterol, fasting blood 
glucose, and creatinine levels were 165, 106, and 0.9 mg/
dL, respectively. 
When we calculated the body composition measures 
of VAT, SAT, and SMA using CT, the median values of 
each measure were 98.9, 106.9, and 107.7 cm2. No sig-
nificant differences were noted regarding the included 
measures according to ANCA variants and ANCA types 
compared to age-, sex-, and BMI-matched healthy con-
trols (Fig. 2).
Comparison of VAT, SAT, and SMA according to the 
presence of comorbidities
Because body composition could be influenced by met-
abolic syndrome prior to AAV diagnosis, the presence 
of comorbidities of hypertension, diabetes, and dyslip-
Table 1. Baseline characteristics of patients with AAV 






MPO-ANCA (or P-ANCA)  
 positivity
79 (67.5)
PR3-ANCA (or C-ANCA) 
  positivity
18 (15.4)
ANCA negativity 25 (21.4)
Demographic data
Age, yr 61.0 (51.0–70.3)
Female sex 74 (63.2)
Height, m 1.6 (1.5–1.7)
Weight, kg 56.0 (50.0–65.0)
BMI, kg/m2 22.0 (19.9–24.3)
BVAS 12.0 (8.0–19.0)
FFS (2009) 1.0 (1.0–2.0)
Follow-up duration, mon 27.3 (10.3–67.9)
Clinical manifestations
General manifestation 58 (49.6)
Cutaneous manifestation 22 (18.8)
Mucous membrane and eye 
 manifestation
5 (4.3)
Ear, nose, and throat 
 manifestation
44 (37.6)
Pulmonary manifestation 77 (65.8)
Cardiovascular manifestation 31 (26.5)
Abdominal manifestation 8 (6.8)
Renal manifestation 71 (60.7)
Nervous system manifestation 41 (35.0)
Comorbidities
Hypertension 46 (39.3)
Diabetes mellitus 23 (19.7)
Dyslipidemia 8 (6.8)
Laboratory data
White blood cell count, /mm3 9,800.0 (6,615.0–13,657.5)
Neutrophil count, /mm3 7,160.0 (4,257.5–10,315.0)
Platelet count, × 103/mm3 331.0 (241.0–418.3)
ESR, mm/hr 68.0 (31.8–102.0)
CRP, mg/L 24.0 (2.2–95.2)
Serum albumin, g/dL 3.3 (2.6–3.8)
Characteristic Value (n = 117)
Total cholesterol, mg/dL 165.0 (133.5–190.3)
Fasting blood glucose, mg/dL 106.0 (92.0–129.3)
Creatinine, mg/dL 0.9 (0.7–2.0)




Values are presented as number (%) or median (interquartile 
range). 
AAV, anti-neutrophil cytoplasmic antibody (ANCA)-associat-
ed vasculitis; MPA, microscopic polyangiitis; GPA, granulo-
matosis with polyangiitis; EGPA, eosinophilic granulomato-
sis with polyangiitis; MPO, myeloperoxidase; P, perinuclear; 
PR3, proteinase 3; C, cytoplasmic; BMI, body mass index; 
BVAS, Birmingham Vasculitis Activity Score; FFS, Five-Fac-
tor Score; ESR, erythrocyte sedimentation rate; CRP, C-reac-
tive protein; VAT, visceral adipose tissue; SAT, subcutaneous 
adipose tissue; SMA, skeletal muscle area. 
Table 1. Continued
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idemia, which are components of metabolic syndrome, 
were investigated according to measures of VAT, SAT, 
and SMA [22]. However, among these comorbidities, 
only the presence of hypertension was more frequent in 
patients with high VAT (58.6% vs. 20.3%, p < 0.001) (Sup-
plementary Table 1). 
Correlation of variables with VAT, SAT, and SMA 
We investigated the correlation of VAT, SAT, and SMA 
measures with different variables. VAT was significant-
ly correlated with age, weight, BMI, and BVAS, whereas 
SAT was correlated with weight, BMI, and creatinine. A 
significant correlation was found between SMA and age, 
height, weight, BMI, and the FFS (2009) (Table 2).
Comparison of clinical outcome measures accord-
ing to VAT, SAT, and SMA
The clinical outcomes of all-cause mortality, ESRD, dis-
ease relapse, ACS, and stroke were compared according 
to VAT, SAT, and SMA measures. Patients with high VAT 
more frequently experienced mortality (22.4% vs. 3.4%, p 
= 0.002), while those with high SAT were less likely to 
develop ESRD (8.6% vs. 25.4%, p = 0.016). Disease relapse 
was less frequent in patients with high SMA (20.7% vs. 
37.3%, p = 0.049) (Supplementary Table 2). In compari-
son, when the clinical outcome measures were evaluated 
according to the presence of sarcopenia, no differences 
in clinical outcomes were observed between the sarcope-
nia and non-sarcopenia groups (Supplementary Table 3).
Factors associated with all-cause mortality and ESRD
To exclude the possibility of length bias, Kaplan-Mei-
er curve analysis was performed to compare the overall, 
renal, and relapse-free survival rates according to VAT, 
SAT, and SMA. Patients with high VAT and low SAT 
had lower overall survival and renal survival rates, re-
spectively (p < 0.001 and p = 0.014) (Supplementary Fig. 
1A and 1B). However, there were no differences in the 
relapse-free survival rate according to SMA (p = 0.097) 
(Supplementary Fig. 1C). In addition, the clinical out-
comes showed no significant differences between pa-
tients with and without obesity (Supplementary Fig. 2).
We performed Cox proportional hazards analysis to 
evaluate factors associated with all-cause mortality and 
ESRD. As shown in Table 3, the diagnosis of MPA, age, 
BVAS, the presence of hypertension, CRP, serum al-
Table 2. Correlation of variables with VAT, SAT, and SMA in patients with AAV
VAT p value SAT p value SMA p value
Age 0.311 < 0.001 0.041 0.660 –0.256 0.005
Height 0.075 0.422 –0.154 0.099 0.582 < 0.001
Weight 0.572 < 0.001 0.339 < 0.001 0.624 < 0.001
BMI 0.702 < 0.001 0.593 < 0.001 0.352 < 0.001
BVAS 0.203 0.028 –0.086 0.354 –0.130 0.162
FFS (2009) 0.122 0.192 –0.087 0.350 –0.183 0.048
White blood cell count 0.057 0.543 –0.107 0.253 0.091 0.329
Neutrophil count 0.120 0.197 –0.122 0.190 0.081 0.385
Platelet count 0.097 0.299 0.163 0.080 0.047 0.613
ESR 0.059 0.527 –0.034 0.713 –0.040 0.666
CRP 0.153 0.101 –0.027 0.773 0.040 0.670
Serum albumin –0.128 0.170 0.013 0.890 0.047 0.614
Total cholesterol 0.065 0.489 0.150 0.108 –0.044 0.641
Fasting blood glucose 0.174 0.060 –0.089 0.342 0.066 0.478
Creatinine –0.048 0.610 –0.210 0.023 0.136 0.145
VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue; SMA, skeletal muscle area; AAV, anti-neutrophil cytoplasmic 
antibody-associated vasculitis; BMI, body mass index; BVAS, Birmingham Vasculitis Activity Score; FFS, Five-Factor Score; 
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.
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Figure 1. Measurement of visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), and skeletal muscle area (SMA) us-
ing computed tomography in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Representative images 
used to measure VAT, SAT, and SMA. Images were obtained from a 72-year-old man (A) and a 56-year-old woman (B).
Figure 2. Comparison of visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), and skeletal muscle area (SMA) ac-
cording to diagnosis and anti-neutrophil cytoplasmic antibody (ANCA) serotype in patients with ANCA-associated vasculitis. 
VAT, SAT, and SMA measures were compared according to diagnosis (A) and ANCA serotype (B) including healthy controls. 
MPA, microscopic polyangiitis; GPA, granulomatosis with polyangiitis; EGPA, eosinophilic granulomatosis with polyangiitis; 
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bumin, creatinine, and high VAT was associated with 
all-cause mortality in univariable analysis. However, 
in multivariable analysis, only creatinine (odds ratio 
[OR], 1.346; 95% confidence interval [CI], 1.034 to 1.753; p 
= 0.027) and high VAT (OR, 7.137; 95% CI, 1.343 to 37.946; 
p = 0.021) were independently associated with all-cause 
mortality. Furthermore, patients with mortality and 
those without mortality showed no differences in terms 
of the administration of immunosuppressive medica-
tions (Supplementary Table 4). In terms of the factors 
related to ESRD, a diagnosis of MPA, BVAS, the pres-
ence of hypertension, total cholesterol, creatinine levels, 
Table 3. Multivariable Cox proportional hazards analysis for factors associated with all-cause mortality in patients with AAV
Variable
Univariable analysis Multivariable analysis
OR (95% CI) p value OR (95% CI) p value
MPA 3.188 (1.006–10.100) 0.049 2.501 (0.645–9.693) 0.185
GPA 1.238 (0.392–3.905) 0.716
EGPAa NA
MPO-ANCA (or P-ANCA) positivity 2.233 (0.626–7.967) 0.216
PR3-ANCA (or C-ANCA) positivity 0.709 (0.159–3.156) 0.652
ANCA negativity 0.218 (0.029–1.669) 0.143
Age, yr 1.069 (1.031–1.165) 0.004 1.051 (0.978–1.130) 0.176
Female sex 0.734 (0.261–2.067) 0.558
Height 0.533 (0.001–224.598) 0.839
Weight 1.027 (0.980–1.077) 0.270
BMI 1.123 (0.960–1.314) 0.146
BVAS 1.098 (1.017–1.185) 0.017 0.974 (0.862–1.099) 0.664
Hypertension 5.291 (1.660–16.868) 0.005 1.271 (0.329–4.901) 0.728
Diabetes mellitus 2.500 (0.846–7.383) 0.097
Dyslipidaemiaa NA
White blood cell count 1.000 (0.999–1.000) 0.474
Neutrophil count 1.089 (0.986–1.204) 0.094
Platelet count 1.000 (0.997–1.004) 0.707
ESR 1.014 (0.999–1.028) 0.054
CRP 1.007 (1.000–1.014) 0.047 1.002 (0.990–1.013) 0.799
Serum albumin 0.260 (0.111–0.610) 0.002 0.454 (0.153–1.348) 0.155
Total cholesterol 0.990 (0.977–1.004) 0.148
Fasting blood glucose 1.003 (0.993–1.013) 0.536
Creatinine 1.341 (1.126–1.597) 0.001 1.346 (1.034–1.753) 0.027
High VAT 8.657 (1.940–38.639) 0.005 7.137 (1.343–37.946) 0.021
High SAT 1.150 (0.417–3.174) 0.787
High SMA 1.761 (0.626–4.960) 0.284
AAV, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis; OR, odds ratio; CI, confidence interval; MPA, mi-
croscopic polyangiitis; GPA, granulomatosis with polyangiitis; EGPA, eosinophilic granulomatosis with polyangiitis; NA, not 
applicable; MPO, myeloperoxidase; P, perinuclear; PR3, proteinase 3; C, cytoplasmic; BMI, body mass index; BVAS, Birming-
ham Vasculitis Activity Score; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; VAT, visceral adipose tissue; SAT, 
subcutaneous adipose tissue; SMA, skeletal muscle area. 
aThe odds ratio was not obtainable because no death was observed in patients with EGPA and dyslipidemia.
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and high SAT was associated with ESRD. Multivariable 
analysis revealed that total cholesterol (OR, 0.983; 95% 
CI, 0.967 to 0.999; p = 0.039) and creatinine (OR, 1.712; 
95% CI, 1.432 to 2.047; p < 0.001) were independent fac-
tors for the development of ESRD (Table 4).
DISCUSSION 
While measures of body composition, such as adipose 
tissue and muscle are increasingly accepted as import-
ant prognostic factors in various diseases, the relation-
ship between body composition and the prognosis of 
AAV is still largely uncertain. In the present study, we 
estimated three different body composition indices, 
Table 4. Multivariable Cox proportional hazards analysis for factors associated with end-stage renal disease in patients with AAV
Variable
Univariable analysis Multivariable analysis
OR (95% CI) p value OR (95% CI) p value
MPA 3.133 (1.134–8.653) 0.028 1.266 (0.367–4.365) 0.709
GPA 0.822 (0.275–2.460) 0.726
EGPA 0.136 (0.018–1.018) 0.052
MPO-ANCA (or P-ANCA) positivity 2.155 (0.719–6.459) 0.171
PR3-ANCA (or C-ANCA) positivity 0.852 (0.248–2.923) 0.799
ANCA negativity 0.366 (0.085–1.577) 0.177
Age 1.017 (0.982–1.054) 0.344
Female sex 1.288 (0.495–3.354) 0.604
Height 0.108 (0.000–18.515) 0.396
Weight 0.960 (0.915–1.006) 0.085
BMI 0.884 (0.760–1.029) 0.112
BVAS 1.092 (1.027–1.163) 0.005 0.995 (0.909–1.090) 0.917
Hypertension 3.261 (1.296–8.206) 0.012 1.616 (0.521–5.020) 0.406
Diabetes mellitus 1.938 (0.743–5.056) 0.176
Dyslipidaemia 0.785 (0.105–5.875) 0.813
White blood cell count 1.000 (0.999–1.000) 0.450
Neutrophil count 1.066 (0.966–1.175) 0.203
Platelet count 0.998 (0.995–1.002) 0.390
ESR 1.004 (0.993–1.015) 0.533
CRP 1.002 (0.995–1.009) 0.628
Serum albumin 0.638 (0.345–1.182) 0.153
Total cholesterol 0.985 (0.973–0.997) 0.016 0.983 (0.967–0.999) 0.039
Fasting blood glucose 1.000 (0.991–1.010) 0.893
Creatinine 1.784 (1.527–2.085) < 0.001 1.712 (1.432–2.047) < 0.001
High VAT 0.697 (0.284–1.709) 0.430
High SAT 0.303 (0.110–0.836) 0.021 0.518 (0.167–1.606) 0.255
High SMA 2.167 (0.864–5.438) 0.099
AAV, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis; OR, odds ratio; CI, confidence interval; MPA, micro-
scopic polyangiitis; GPA, granulomatosis with polyangiitis; EGPA, eosinophilic granulomatosis with polyangiitis; MPO, my-
eloperoxidase; P, perinuclear; PR3, proteinase 3; C, cytoplasmic; BMI, body mass index; BVAS, Birmingham Vasculitis Activity 
Score; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; VAT, visceral adipose tissue; SAT, subcutaneous adipose 
tissue; SMA, skeletal muscle area. 
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namely VAT, SAT, and SMA, using CT in patients with 
AAV. Among the estimated body composition measures, 
VAT was associated with disease activity in patients with 
AAV, and high VAT was independently associated with 
all-cause mortality along with serum creatinine levels, 
which is a well-known prognostic factor in AAV. The 
findings of our study imply that assessment of VAT may 
aid in assessing disease activity and identifying subjects 
with increased risk of mortality in patients with AAV.
There is abundant evidence in the literature support-
ing the association between high VAT and all-cause 
mortality found in the present study. Obesity is char-
acterized by an increase in adipose tissue in the body, 
which is a condition of impaired immunity leading to 
chronic inflammation [23]. In obesity, the expression of 
proinflammatory cytokines and chemoattractants is in-
creased in the adipose tissue and VAT is regarded as the 
major source [24]. Moreover, adipose tissue is composed 
of different cell types such as adipocytes, fibroblasts, 
vascular endothelial cells, and immune cells. Chang-
es that occur in the adipose tissue microenvironment 
found in obesity could lead to the polarization of im-
mune cells into an inflammatory phenotype (ie., the ex-
pansion of M1 macrophages and inflammatory helper 
T cells), which further amplify and perpetuate the im-
mune response [23]. Furthermore, considering the fact 
that a higher degree of inflammation is associated with 
increased mortality in the general population [25], it can 
be speculated that higher VAT is associated with a lower 
survival rate in patients with auto-inflammatory disor-
ders, particularly AAV. Of note, VAT was correlated with 
BVAS, which is the most widely used measure to assess 
disease activity in AAV, rather than with ESR and CRP, 
suggesting that VAT could play a role in the inflamma-
tory process in AAV independent of conventional acute 
phase reactants.
In contrast to VAT, SAT is considered to possess a 
protective effect on patient prognosis in various cancers 
[26,27]. Although the precise physiological mechanism 
by which SAT regulates inflammation is largely unclear, 
the opposite effect of SAT compared to that of VAT can 
be partly explained by the “adipose tissue overflow hy-
pothesis,” which explains that the accumulation of VAT 
increases when energy storage in SAT exceeds the nor-
mal limit [28]. In line with this finding, we found that 
SAT was inversely associated with ESRD in univariable 
Cox proportional hazards analysis, although its signifi-
cance was not evident in multivariable analysis. Mean-
while, the total cholesterol level was found to be an inde-
pendent protective factor of ESRD along with creatinine 
levels. Because dyslipidemia is associated with adverse 
renal outcomes in general [29], this finding might be 
considered rather counterintuitive. However, this para-
doxical association seems to be relevant to the malnutri-
tion induced by inflammation, as several epidemiologic 
studies have demonstrated that lower total cholester-
ol levels are inversely correlated with the incidence of 
ESRD [30]. 
As expected, when we evaluated the correlation be-
tween body composition measures with different vari-
ables, a strong association was found between VAT and 
SAT with weight and BMI. These findings are in line 
with the understanding that weight and BMI, which are 
the most commonly used methods to assess obesity, are 
increased with the accumulation of corporal adipose 
tissue. On the other hand, obesity is strongly associated 
with metabolic syndrome [31]. However, on investigat-
ing the medical comorbidities comprising metabolic 
syndrome, we found that only the presence of hyper-
tension, but not diabetes mellitus or dyslipidemia, was 
significantly different between patients with high and 
low VAT. In addition, when we divided our patients into 
obese and non-obese groups and compared the clini-
cal outcomes, no difference in the patient prognosis 
was found. These findings suggest that the interplay 
between adiposity and the pathogenesis of AAV may be 
complex and may not be exclusively accounted for al-
tered metabolism. 
Recently, it has been suggested that patients with AAV 
exhibit several different characteristics according to the 
variants and ANCA types [32]. However, in our subgroup 
analysis based on AAV variants and ANCA types, there 
was no difference in specific body composition variables 
between groups, even in comparisons with age-, sex-, 
and BMI-matched healthy controls. Therefore, it could 
be suggested that VAT, SAT, and SMA have limited clin-
ical value for differentiating patients with AAV subtypes 
from healthy controls.
Sarcopenia refers to a condition of decreased skel-
etal muscle mass, which is closely associated with an-
thropometric measures as well as the aging process [33]. 
Consistently, in this study, an inverse correlation was 
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found between age and SMA and a positive correlation 
was identified between height, weight, BMI, and SMA. 
However, recent studies have shown that sarcopenia 
could also be influenced by inflammation via the cata-
bolic effects of proinflammatory cytokines, and that it 
predicts adverse clinical outcomes by serving as a surro-
gate marker of systemic inflammation and malnutrition 
[34,35]. Interestingly, we found a significant inverse cor-
relation between SMA and FFS (2009), which is an estab-
lished prognostic factor in AAV, although SMA was not 
significantly correlated with ESR or CRP. Nevertheless, 
high SMA was not associated with lower relapse-free 
survival on Kaplan-Meier analysis. Moreover, when the 
definition of sarcopenia, derived by the Korean National 
Health and Nutritional Examination Surveys was ap-
plied [17], it was not associated with any of the clinical 
outcome measures. Thus, it seems that the definition 
and clinical significance of sarcopenia may not be gen-
eralized and should be cautiously adopted depending 
on the underlying medical condition.
Obesity, especially high VAT levels, has previously 
been reported to be a relevant factor in the develop-
ment of cardiovascular events in the general population 
[36]. Interestingly, a recent publication by Briot et al. [37] 
evaluated VAT and SAT by DXA and demonstrated that 
a high VAT-to-SAT ratio predicts major cardiovascular 
events in patients with systemic necrotizing vasculitis. 
In contrast, there were no differences in the outcomes 
of ACS and stroke according to VAT or SAT, as well as 
the VAT-to-SAT ratio, in our study. Notably, the values 
of VAT and SAT in the study by Briot et al. [37] were 
much higher (mean VAT, 121.6 and SAT, 281.0), and the 
mean BMI value was also higher than that in our cohort. 
Considering the differences in baseline values of body 
composition and the patients’ ethnic groups, this might 
have influenced the discrepant result from our study 
with that of Briot et al. [37]. In addition, the relatively 
short follow-up duration in our study and the differenc-
es in definitions of clinical parameters should also be 
taken into account. Conversely, there are several advan-
tages in our study. First, all data were collected from a 
single center, which makes our study less prone to in-
terobserver or intercenter variability. Second, both CT 
and MRI are currently gold standard methods for the 
measurement of abdominal adipose tissue [38]. There-
fore, CT could be more accurate for assessing VAT and 
SAT. Third, we measured SMA and investigated its clin-
ical significance together with those of VAT and SAT. 
Fourth, besides cardiovascular events, other clinical out-
comes including all-cause mortality, ESRD, and disease 
relapse were evaluated, further emphasizing the value of 
assessing body composition measures in AAV. 
There are several limitations in this study. First, be-
cause the study design was retrospective, data were col-
lected by reviewing electronic medical records. Second, 
although identical criteria were used to estimate VAT, 
SAT, and SMA, differences in imaging modalities might 
have influenced the calculation of body composition 
measures. Third, because CT is not an essential imaging 
study for AAV, it may have been performed in patients 
with severe clinical manifestations or uncertain inflam-
matory foci at the initial presentation. Furthermore, 
patients with renal involvement might have been less 
likely to undergo CT. Thus, the characteristics of our 
study population may not represent the general charac-
teristics of all AAV patients. Fourth, there are concerns 
regarding the poor level of agreement between skeletal 
mass measured using CT and other parameters such as 
BIA findings and the mid-arm muscle circumference; 
furthermore, it is uncertain whether SMA in L3 is rep-
resentative of the skeletal mass for defining sarcopenia. 
Finally, it is still unknown whether measures to reduce 
VAT (i.e., exercise and diet control) are beneficial in pa-
tients with AAV. Additional investigations are warranted 
to verify the results of our study and to elucidate the im-
pact of body composition in AAV.
In conclusion, our study demonstrated that among 
body composition measures, VAT was associated with 
disease activity and high VAT levels were independently 
associated with all-cause mortality in patients with AAV. 
Estimation of VAT could aid in estimating the disease 
activity and identifying subjects with an increased risk 
of mortality in patients with AAV.
KEY MESSAGE
1. Among the body composition indices mea-
sured by quantitative computed tomography 
(CT), visceral adipose tissue (VAT) was asso-
ciated with disease activity in patients with 
antibody-associated vasculitis (AAV).
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Supplementary Table 3. Comparison of clinical outcome measures according to the presence of sarcopenia in patients with AAV
Clinical outcome Sarcopenia group (n = 30) Non-sarcopenia group (n = 87) p value
Mortality (+) 5 (16.7) 10 (11.5) 0.467
Mortality (–) 25 (83.3) 77 (88.5)
ESRD (+) 6 (20.0) 14 (16.1) 0.625
ESRD (–) 24 (80.0) 73 (83.9)
Disease relapse (+) 9 (30.0) 25 (28.7) 0.896
Disease relapse (–) 21 (70.0) 62 (71.3)
Acute coronary syndrome (+) 0 4 (4.6) 0.571
Acute coronary syndrome (–) 30 (100.0) 83 (95.4)
Stroke (+) 1 (3.3) 6 (6.9) 0.676
Stroke (–) 29 (96.7) 81 (93.1)
Values are expressed as number (%). 
AAV, anti-neutrophil cytoplasmic antibody-associated vasculitis; ESRD, end-stage renal disease.
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Supplementary Table 4. Immunosuppressive medications administered to patients with AAV with and without mortality 
Immunosuppressive medications Patients with mortality (n = 15) Patients without mortality (n = 102) p value
Glucocorticoid 14 (93.3) 92 (90.2) 0.999
Cyclophosphamide 6 (40.0) 53 (52.0) 0.389
Mycophenolate mofetil 2 (13.3) 8 (7.8) 0.615
Azathioprine 4 (26.7) 37 (36.3) 0.571
Tacrolimus 2 (13.3) 4 (3.9) 0.170
Rituximab 3 (20.0) 8 (7.8) 0.149
Methotrexate 1 (6.7) 5 (4.9) 0.569
Values are expressed as number (%).
AAV, anti-neutrophil cytoplasmic antibody-associated vasculitis. 
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Supplementary Figure 1. Kaplan-Meier curve analysis for overall, renal, and relapse-free survival rates according to visceral 
adipose tissue (VAT), subcutaneous adipose tissue (SAT), and skeletal muscle area (SMA) in patients with anti-neutrophil cyto-
plasmic antibody-associated vasculitis. The overall survival rate (A), renal survival rate (B), and relapse-free survival rate (C) are 
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Supplementary Figure 2. Comparison of clinical outcome measures between obese and non-obese patients with anti-neutro-
phil cytoplasmic antibody-associated vasculitis (AAV). The overall survival rate (A), renal survival rate (B), relapse-free survival 
rate (C), acute coronary syndrome (ACS)-free rate (D), and stroke-free rate (E) are compared between obese and non-obese pa-
tients with AAV. 
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